Millennium Management’s ImmunityBio IBRX Stock Holding History

Millennium Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100,000	Closed	-$537K	–	6178
2024 Q1	$537K	Buy	+100,000	New	+$453K	﹤0.01%	4763
2021 Q2	–	Sell	-100,000	Closed	-$2.37M	–	6752
2021 Q1	$2.37M	Buy	+100,000	New	+$2.59M	﹤0.01%	3371
2016 Q2	–	Sell	-50,000	Closed	-$411K	–	3342
2016 Q1	$411K	Hold	50,000	–	–	﹤0.01%	2618
2015 Q4	$867K	Buy	+50,000	New	+$742K	﹤0.01%	2371

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management's IBRX Position: Q1 2026 in Review

Millennium Management increased its ImmunityBio (IBRX) stake by 1,099% in Q1 2026, buying an estimated $8.91M and bringing the position to 1,420,244 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2094.

Millennium Management first reported a position in IBRX in Q1 2016 and has held it in 36 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Millennium Management held 1,420,244 shares of ImmunityBio worth $10.9M as of Q1 2026.
Millennium Management bought 1,301,816 ImmunityBio shares in Q1 2026, an estimated $8.91M.
ImmunityBio made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2094 holding.
Millennium Management first reported a position in ImmunityBio in Q1 2016 and has held it in 36 quarters since.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.